Eli Lilly & Co said its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year. The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label than expected to treat rheumatoid arthritis. There are few available treatments for lupus, which affects multiple organs and tissues in the body, causing symptoms that range from extreme fatigue and unexplained fever to joint pain and rash. After 24 weeks of therapy, 67 percent of patients on a 4 mg dose of baricitinib showed a resolution of arthritis or rash, common symptoms of lupus, compared with 53 percent on a placebo. However, baricitinib’s 2 mg dose did not show a statistically significant improvement. Lilly’s once-daily pill belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, and Lilly says it is ahead of the curve in testing the drug in lupus patients. “This is the first of this class of therapies to have shown this sort of benefit and we want to make the most of that,”… Read full this story
- Top 10 Tips To Successful Home Staging!
- Herbal Supplement For HIV - AIDS Is Successful In Clinical Trial
- Lupus and Pregnancy - What to Consider Before You Decide to Have a Baby
- Getting the Right Treatment for Skin Cancer
- Information On Obesity Treatment Medicine
- The Key to Early Prevention and Treatment of Cancer
- Get Over It - Overcoming Your Resistance to Personal Success
- A Simple Start to Home Staging
- Accounting For Successes And Failures
- Dare to Dream, the First Step Towards the Top of Success
Lupus Treatment is Successful in Mid-Stage Trial have 278 words, post on www.newsmax.com at June 14, 2018. This is cached page on Vietnam Dance. If you want remove this page, please contact us.